

Lyka Generics Limited

6, Ground Floor, Himalaya House, Ramabai Ambedkar Marg, Crawford Market, Fort Mumbai - 400 001.
Phone: 022 6611 2200 CIN: U85100MH2013PLC241035

25th September 2023

BSE Ltd.

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051.

Script Code: 500259

Script Code: LYKALABS

Dear Sir/Madam,

Sub.: Disclosure under Reg. 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011


I, Narendra Rathod, Director of Lyka Generics Limited which is a Promoter/ Promoter Group of Lyka Labs Limited; file herewith disclosure in the prescribed format under Regulation 29 (2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011; for purchase of 7,900 equity shares of Lyka Labs Limited form open market.

I request you to take the above disclosure on your record.

Thanking you,

Yours Faithfully,

For Lyka Generics Limited



Narendra Rathod

Director

(DIN: 09719860)

Encl.: A/a.

C.C.:

Lyka Labs Limited

Registered Office:

4801/B & 4802/A,

GIDC, Industrial Estate,


Ankleshwar 393 002.

Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Lyka Labs Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the Acquirer	Acquirer Lyka Generics Limited (formerly known as Lyka Animal Healthcare Limited) Persons Acting in Concert Nehal N. Gandhi Kunal Gandhi Enai Trading and Investment Private Limited		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. BSE Limited 2. The National Stock Exchange of India Limited		
Details of the acquisition as follows:	Number of shares	% w.r.t. total share / voting capital wherever Applicable	% of total diluted share/voting capital of TC
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights			
Nehal N. Gandhi	23,25,082	7.03%	7.03%
Kunal N. Gandhi	24,19,152	7.31%	7.31%
Enai Trading and Investment Private Limited	9,93,827	3.00%	3.00%
Lyka Generics Limited (formerly know as Lyka Animal Healthcare Limited)	12,100	0.04%	0.04%
Total	57,50,161	17.38%	17.38%
b) Shares in the nature of encumbrance (pledge/lien/ non-disposal undertaking/ others)	NIL	NIL	NIL
c) Voting rights (VR) otherwise than by equity shares	NIL	NIL	NIL
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	NIL	NIL	NIL
Total (a+b+c+d)	57,50,161	17.38%	17.38%
Details of Acquisition			
a) Shares carrying voting rights			
Nehal N. Gandhi	4,918	0.01%	0.01%
Kunal N. Gandhi	5,848	0.02%	0.02%
Enai Trading and Investment Private Limited	6,173	0.02%	0.02%
Lyka Generics Limited (formerly know as Lyka Animal Healthcare Limited)	7,900	0.02%	0.02%

b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	NIL	NIL	NIL
c) Voting rights (VR) otherwise than by equity shares	NIL	NIL	NIL
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	NIL	NIL	NIL
Total (a+b+c+d)	24,839	0.07%	0.07%
After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rights			
Nehal N. Gandhi	23,30,000	7.04%	7.04%
Kunal N. Gandhi	24,25,000	7.33%	7.33%
Enai Trading and Investment Private Limited	10,00,000	3.02%	3.02%
Lyka Generics Limited (formerly know as Lyka Animal Healthcare Limited)	20,000	0.06%	0.06%
Total	57,75,000	17.45%	17.45%
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	NIL	NIL	NIL
c) Voting rights (VR) otherwise than by equity shares	NIL	NIL	NIL
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	NIL	NIL	NIL
Total (a+b+c+d)	57,75,000	17.45%	17.45%
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	Open Market		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc	Equity shares carrying voting rights		
Date of acquisition of /—date of receipt of intimation of allotment of shares /—VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	22nd September 2023		
Equity share capital / total voting capital of the TC before the said acquisition	3,30,90,000 equity shares		
Equity share capital/ total voting capital of the TC after the said acquisition	3,30,90,000 equity shares		
Total diluted share/voting capital of the TC after the said acquisition	3,30,90,000 equity shares		

For Lyka Generics Limited


Narendra Rathod
 Director
 (DIN: 09719860)



Mumbai, 25th September 2023.